1	BNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2
2	S1 and S2
3	
4	R. Camille Brewer ¹ , Nitya S. Ramadoss ¹ , Lauren J. Lahey ² ,
5	William H. Robinson ^{1,*} , Tobias V. Lanz ^{1,3,*}
6	
7	Affiliations
8	¹ Division of Immunology and Rheumatology, Department of Medicine, Stanford University
9 10	School of Medicine, 269 Campus Drive, Stanford, CA 94305, United States, and the VA Palo Alto Health Care System 3801 Miranda Ave. Palo Alto, CA 94304 United States
11	² Biophysics Program, Stanford University, ChEM-H Building, 290 Jane Stanford Way,
12	Stanford, CA 94305
13	³ Department of Neurology, Mannheim Center for Translational Neurosciences (MCTN),
14 15	Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim Germany
16	
17	*equal contributions, corresponding authors
18	
19	
20	The first ever messenger RNA (mRNA) vaccines received emergency approvals in
21	December 2020 and are highly protective against SARS-CoV-2 ¹⁻³ . However, the
22	contribution of each dose to the generation of antibodies against SARS-CoV-2 spike (S)
23	protein and the degree of protection against novel variants, including delta, warrant
24	further study. Here, we investigated the B cell response to the BNT162b2 vaccine by
25	integrating repertoire analysis with single-cell transcriptomics of B cells from serial blood
26	collections pre- and post-vaccination. The first vaccine dose elicits highly mutated $\mathbf{IgA^{+}}$
27	plasmablasts against the S protein subunit S2 at day 7, suggestive of recall of a memory B
28	cell response generated by prior infections with heterologous coronaviruses. On day 21, we
29	observed minimally-mutated $\mathbf{IgG}^{\scriptscriptstyle +}$ activated switched memory B cells targeting the
30	receptor binding domain (RBD) of the S protein, likely representing a primary response
31	derived from naïve B cells. The B cell response against RBD is specifically boosted by the
32	second vaccine dose, and encodes antibodies that potently neutralize SARS-CoV-2
33	pseudovirus and partially neutralize novel variants, including delta. These results
34	demonstrate that the first vaccine dose activates a non-neutralizing recall response

predominantly targeting S2, while the second vaccine dose is vital to boosting neutralizing anti-S1 RBD B cell responses.

37 BNT162b2 is one of the two first widely available vaccines that are based on lipid 38 nanoparticle delivery of modified mRNA and is dependent on the host cells for translation and cell surface expression of the SARS-CoV-2 spike (S) protein⁴. S consists of two subunits, S1 and 39 40 S2. The S1 subunit contains the receptor binding domain (RBD) that binds human ACE2 and initiates viral cell entry, while S2 mediates viral cell membrane fusion^{5,6}. RBD is the target of 41 most neutralizing antibodies found in COVID-19 patients⁷. Serological and repertoire studies 42 from COVID-19 patients have characterized neutralizing antibodies to S protein^{1,2,8,9}. However, 43 44 the cellular processes that lead to potent neutralizing antibodies in response to mRNA vaccines 45 are not fully characterized and to what degree these antibodies protect against novel variants 46 remains unclear.

47 Single-cell sequencing of B cells

Nine healthy individuals were included in this study, all naive to prior SARS-CoV-2 48 49 infection (Extended Data Table 1). One individual contracted symptomatic and PCR-positive 50 COVID-19 eight weeks after the second vaccine. Magnetically enriched peripheral blood B cells 51 were investigated by droplet-based single-cell sequencing prior to the first vaccination (D0), as 52 well as 7-9 days (D7), 21-23 days (D21), and 28 days (D28) after the first vaccination (Fig. 1a). 53 All individuals received their second dose on D21. In addition, SARS-CoV-2 S-specific B cells 54 were labeled with S1, S2, and RBD tetramers conjugated to fluorochromes and DNA-barcodes, and FACS-sorted before sequencing (Fig. 1a). A total of 131,138 B cells (~3600 per sample) 55 56 were included in the global B cell transcriptomic analysis. Dimensionality Reduction by Uniform Manifold Approximation and Projection (UMAP)¹⁰ and graph-based clustering distinguished 57 58 nine B cell populations present in all individuals at all four timepoints, including the canonical naïve B cell, unswitched memory (UM) and switched memory (SM) B cell, and plasmablast 59 60 (PB) clusters (Fig. 1b, Extended Data Fig. 1a-b). Naive B cells and SM were further categorized 61 into resting and activated populations by CD24 and CD86 gene expression (Extended Data Fig. 1c-e)¹¹. Cluster assignments are supported by isotype proportions and mutation frequencies 62 (Extended Data Fig. 1f-g). 63



64

Fig. 1: Single cell transcriptomic analysis of the B cell response following BNT162b2 vaccination.
a, Outline of experimental approach. b, UMAP visualization of single-cell B cell transcriptome sequencing
data of all individuals at four timepoints. B cell cluster assignments are based on gene expression and
cell surface expression (CITE-seq) of canonical B cell markers. c, Mean percentages of B cell subtypes
shown in (b). d, Individual and mean percentages of B cell types in (b) at four timepoints. *n=*9 individuals
at all timepoints. Individual values, means and standard deviations are shown. ***P*<0.01, ****P*<0.001,

- 70 at all timepoints. Individual values, means and standard deviations are shown. ""P < 0.01, """P < 0.01
- 71 *****P* <0.0001 according to two-tailed one-way ANOVA test in comparison to the first timepoint.

72 Unswitched memory (UM) differentiation into resting memory B cells (RSM) in response to

73 vaccination

To evaluate changes in the B cell transcriptome in response to the mRNA vaccine, B cell
subtypes were followed over time (Fig. 1b-d). Strikingly, UM decreased after the initial

76 vaccination, while RSM expanded (Fig. 1c,d). To track the diminishing UM, we followed 77 clonally expanded UM from D0 to the post-vaccination timepoints by their clonal B cell receptor 78 (BCR) sequences (Fig. 2a). Pre-vaccine UM develop into RSM in response to vaccination, with 79 no significant change in mutation load (Fig. 2a, Extended Data Fig. 2a-b), suggesting 80 differentiation without germinal center (GC) maturation. Clonal UM and RSM have little 81 connectivity to PB or activated switched memory (ASM) B cell clusters, indicating activation 82 and differentiation of UM is independent of the antibody response against SARS-CoV-2 (Fig. 2a, Extended Data Fig. 2c). Pathway enrichment analysis of UM and RSM determined significant 83 changes in leukocyte activation, cytokine signaling, and B cell signaling pathways post 84 85 vaccination (Extended Data Fig. 3a,b). Accordingly, we observed increased expression of B cell 86 signaling and activation genes in UM (Fig. 2b). In contrast, we observed downregulation of the same genes in RSM after vaccination (Fig. 2c). However, upregulation of CD83 and CD69 in 87 RSM indicates recent activation (Extended Data Fig. 3d,e)^{12,13}. Together, this suggests that 88 vaccination activates UM and induces class-switching and differentiation into RSM, independent 89 90 of the GC. RSM, once differentiated, downregulate their activation levels.

91 PB and ASM recruitment in response to vaccination

PB are short-lived, activated B cells that expand in response to antigen stimulation and 92 secrete large amounts of antibodies¹⁴. In contrast to strong PB expansions in other vaccination 93 settings¹⁵, overall PB numbers in our study only slightly increase post SARS-CoV-2 vaccination 94 95 (Fig. 1d, Extended Data Fig. 4a). To identify B cell populations directly involved in the antigen-96 specific response, we focused on clonal B cell expansions that include PB at D28 (Fig. 2d). 97 Based on shared BCR sequences, we found strong connectivity between the PB, dividing PB, 98 and ASM subsets (Fig. 2d, Extended Data Fig. 2c). Genes associated with leukocyte activation 99 and protein processing are enriched in PB, consistent with their function as antibody producers 100 (Extended Data Fig. 3c). Enrichment of genes associated with SARS-CoV-2 infection at D21 101 suggests that recognition of viral proteins trigger similar pathways in immunization and infection 102 (Extended Data Fig. 3c). Overall, the majority of genes associated with B cell activation increase 103 over time in response to vaccination (Fig. 2e).



104

105 Fig. 2: Unswitched memory B cell differentiation and expansion of IgG⁺ plasmablasts in response 106 to vaccination. a, Alluvial plot of B cell trajectories (left) across timepoints and UMAP projection (right) of 107 clonally expanded B cells that are related to at least one UM at D0. Clonal expansions included have ≥3 108 members at ≥2 timepoints. b-c, Gene expression in UM (b) and RSM (c) of genes involved in B cell 109 signaling and activation. d, Alluvial plot of B cell trajectories (left) and UMAP projection (right) of clonally 110 expanded B cells that are related to at least one PB at D28. Clonal expansions included have ≥ 3 111 members at ≥ 2 timepoints. e, Gene expressions of activation markers in PB. f, Percentage of IgG⁺ PB per 112 individual (n=9), at four timepoints. **q**, Average mutation frequency of IqG⁺ PB per individual (n=9) at four timepoints. Individual values, means and standard deviations are shown. *P < 0.05; or **P < 0.01 113 114 according to two-tailed one-way ANOVA test in comparison to the first timepoint.

- In health, a high proportion of peripheral blood PB are IgA⁺ due to ongoing immune
 responses at the mucosal barriers. IgG⁺ PB of non-mucosal origin increase during systemic
 infection and exercise 1617. Comparently, and hence a low increase in LeC⁺ PD are much after
- 118 infection and vaccination^{16,17}. Congruently, we observed an increase in IgG⁺ PB one week after

119 the first and second vaccination, respectively (Fig. 2f, Extended Data Fig. 4b-e), with strongest

expansions in the inflammatory subtypes IgG1 and IgG3 (Extended Data Fig. 4c). The average

121 mutation frequencies of IgG^+ PB decrease over time, indicative of an influx of cells into PB from

the naïve B cell pool rather than from memory B cells (Fig. 2g). Together, our results show that

123 clonal PB and ASM are closely connected, and new, low mutation IgG⁺ PB are recruited in

124 response to vaccination.

125 S-specific B cells expand in response to vaccination

126 To further characterize the S-specific B cell response to vaccination, we labeled B cells 127 with fluorescently labeled S1, S2, and RBD antigen tetramers, each with unique barcodes, and 128 FACS-sorted tetramer-specific and non-specific IgA⁺/G⁺ PB and IgA⁺/G⁺ SM (Extended Data 129 Fig. 5a). Antigen-specificity of each single B cell could be determined by their barcode after 130 demultiplexing (Extended Data Fig. 6a-d). In contrast to the global PB population (Fig. 1d), and 131 in line with our observation on the IgG⁺ PB population (Fig. 2f), S-specific IgA⁺/G⁺ PB strongly 132 expand one week after the initial vaccination and to a lesser degree after the second vaccination 133 (Fig. 3a, Extended Data Fig. 5b). The S-specific IgA^+/G^+ SM response increases over time from 134 D7 to D28 (Fig. 3b, Extended Data Fig. 5d). Both S-specific populations, SM and PB, shift from IgA⁺ to IgG⁺ over time (Fig. 3c, Extended Data Fig. 5c,e). 135

136 Differential B cell response to S1 and S2

137 Vaccine studies have shown that antibody responses against distinct epitopes contribute differentially to immune protection¹⁸. Here, we investigated how the antibody response to each 138 139 subunit of S varies within B cell subsets and over time. UMAP-analysis revealed that S2-specific 140 B cells are predominantly PB and appear in large numbers as early as D7 (Fig. 3d-f). In contrast, 141 the majority of RBD-specific B cells and B cells that bind S1 but not RBD (S1n) are ASM (Fig. 142 3d,e, Extended Data Fig. 5f). Additionally, the RBD and S1n-specific B cells need longer to 143 develop, accounting for less than 20% of S-specific B cells on D7 and over 50% by D28 (Fig. 144 3d-f,). The S2-specific PB response is highly clonal and IgA1⁺ dominated, while RBD and S1n-145 specific ASM use predominantly IgG1, and are less clonally expanded than S2 PB (Fig. 3g,h). 146 The rapid recall of S2 and delayed S1 response indicates that the S2 B cell response is a 147 secondary response, while the B cell response to RBD is a primary response.



148 Fig. 3: Vaccination induces a IgA⁺ anti-S2 response on day 7 followed by IgG⁺ RBD response on 149 days 21 and 28. a-c, Quantification of flow cytometry data, showing percentages of a, anti-S PB, and b, 150 anti-S SM in all B cells at four timepoints. c. Percentage of IgG⁺ anti-S SM in all anti-S SM at four 151 timepoints. . n=9 individuals per timepoint. Individual data points are averages of two independent 152 experiments. d, UMAP visualization of demultiplexed transcriptomic data of anti-S⁺ and anti-S⁻ sorted B 153 cells, showing cluster assignments of memory (blue), activated memory (turquoise), and PB (red) (left) 154 and antigen-specificity to S2 (orange), RBD (green), and S1n (blue) (right). e-h, Proportions of sorted 155 cells shown in (d), separated by antigen and by e, cluster distribution, f, timepoint, g, clonality, and h, 156 isotype. i, Plasma IgG levels against S2 (left), RBD (center), and S1 (right) for n=9 individuals at four 157 timepoints. AUC for plasma dilutions are shown. j, Plasma neutralization curves (left) and quantification 158 (NT50) of neutralization titers (right) of n=9 individuals at timepoints post vaccination. k, V-gene mutation 159 frequencies (number of mutations per length of V-gene) of B cells specific for S2 (left), RBD (center), and 160 S1n (right) at timepoints post vaccination. Dashed line indicates the average mutation frequency of sorted 161 antigen negative B cells. Individual data points represent single B cells from n=9 individuals. Means and 162 standard deviations are shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 according to two-tailed 163 one-way ANOVA test in comparison to the first timepoint displayed and g-j, chi-square test.

164 The early S2 PB response is echoed by the early development of anti-S2 plasma 165 antibody titers, which start leveling off at D21. Strikingly, RBD and S1 IgG and IgA titers 166 remain low until day 28, one week after the second vaccination (Fig. 3i, Extended Data Fig. 7a-167 d). Accordingly, plasma neutralization of SARS-CoV-2 Wuhan-Hu-1 pseudovirus is 168 significantly boosted after the second vaccination (Fig. 3j). As primarily anti-RBD antibodies 169 have the potential to block viral entry into the cell, this differentiation is critical and highlights 170 the importance of the second injection for a protective anti-RBD response. Notably, it is 171 overlooked in studies that focus solely on the anti-S antibody response.

172 Interestingly, one study participant contracted COVID-19 eight weeks after the second 173 vaccination. The individual exhibited the lowest IgG and IgA titers for RBD and the lowest 174 plasma neutralization potency following both vaccine doses in the tested cohort (Extended Data 175 Fig. 8a-c). While this individual did produce B cells with high-affinity neutralizing BCR 176 sequences (P1 in Fig. 4e,f), antibody secretion seemingly did not occur on sufficient levels. 177 Antibody titers did not increase significantly even two weeks after the infection (Extended Data 178 Fig. 8d), suggesting that low antibody titers in this individual are not confined to the mRNA 179 vaccine.

180 Influ

30 Influx of minimally-mutated anti-RBD B cells

181 During antigen-specific B cell responses, BCR sequences tend to accumulate mutations 182 during affinity maturation¹⁹. In contrast, neutralizing antibodies from COVID-19 patients show 183 characteristically low mutation rates, indicating recruitment of naïve B cells to the GC in 184 response to a novel antigen that has little structural overlap with previously encountered 185 pathogens²⁰. In our study, D7 B cells specific for any of the three antigens showed mutation 186 frequencies similar to the antigen-negative sorted B cells, suggesting that this initial response 187 stems directly from the memory B cell pool (Fig. 3k). At this early timepoint, S2-specific B cells 188 predominate over RBD and S1n-specific B cells, providing further evidence that the rapid 189 memory recall response is more effective for S2 than S1 (Fig. 3f, k). Consistent with this 190 observation, S2 is more conserved among human pathogenic coronaviruses than S1^{21,22}. Strikingly, at timepoints D21 and D28, with the influx of S1-specific B cells, mutation 191 192 frequencies decrease (Fig. 3k). Together, these results indicate new recruitment from the naïve B 193 cell pool and short GC maturation in response to the vaccine.

194 Vaccine-induced neutralization of variants

195 To test if these newly-recruited, minimally mutated anti-S antibodies are better at binding 196 the S subunits than the early, highly mutated anti-S antibodies recruited from the memory B cell 197 pool, we expressed 50 representative BCR sequences as recombinant monoclonal antibodies 198 (rmAbs) — 14 from S2-specific, 30 from S1/RBD-specific, and 6 from S1n-specific B cells 199 (Extended Data Table 2). Of those selected antibodies, 8 rmAbs bound S2, 15 rmAbs bound 200 RBD, and 3 rmAbs bound S1 but not RBD, as measured by ELISA and bio-layer interferometry 201 (Fig. 4a and Extended Data Fig. 9). Interestingly, when we compared low and high binding anti-202 S1 rmAbs (encompassing RBD and S1n) we found that high binding rmAbs show significantly 203 lower mutation frequencies than low binding anti-S1 rmABs (Fig. 4b). In contrast, mutation 204 frequencies of rmAbs against S2 did not differ significantly between low and high binders (Fig. 205 4c). Additionally, the S2 binders with the highest affinities were derived from D7 PB, while 206 highest affinity antibodies against S1 and RBD stemmed from D21 and D28 (Fig. 4a). S2 is the more highly conserved subunit of S^{22,23} To determine if the rmAbs were cross-reactive to other 207 208 beta-coronaviruses, we tested the highest binders to RBD and S2 against the spike protein of four 209 pathogenic beta-coronaviruses - HCoV-229E, HCoV-HKU1, HCoV-NL63, HCoV-OC43. Of 210 note, nine of the 12 rmAbs against S2 cross-react with HCoV-OC43 spike protein. Conversely, 211 none of the tested anti-RBD rmAbs are cross-reactive to non-SARS-CoV-2 coronaviruses 212 (Extended Data Figure 10). These results corroborate that anti-S2 B cells originate from a recall 213 memory response to heterologous coronaviruses, while in order to generate protective high-214 affinity anti-RBD antibodies, maturation of naïve cells to PB and ASM is required. While increased affinity correlating with low mutation frequency is counter-intuitive, it is characteristic 215 for the B cell repertoire in COVID-19 patients^{24,25}, and likely caused by the novelty of S protein 216 217 with little structural overlap to other pathogens, requiring strong recruitment from the naïve B 218 cell pool.

The emergence of novel SARS-CoV-2 variants poses additional challenges to the management of the pandemic, and could jeopardize vaccine efficacy and the prospects of an expeditious return to normalcy. RBD mutations contribute significantly to immune escape. To evaluate the effects of variants on antibody neutralization, we selected ten high-affinity Wuhan-Hu-1neutralizing anti-RBD rmAbs from three individuals (P1, P2, P6) with different levels of plasma neutralization against delta (Fig. 4d-f). Five different SARS-CoV-2 variants of concern



225

226 Fig. 4: Neutralization of SARS-CoV-2 pseudovirus and variants by BNT162b2-induced antibodies. 227 a, recombinant mAbs derived from BNT162b2-induced B cells bind S2, S1 RBD, and S1.Two-column 228 heatmaps show barcoded tetramer sequencing data (PE and APC labeled) represented as centered log 229 ratio transformed (CLR) counts. Bar graphs show binding of rmAbs generated from the corresponding B 230 cells, represented as area under the curve (AUC) of serial dilutions, measured by ELISA. Threshold, 231 represented as 0, was set to the average binding to BSA plus three times the standard deviation of 232 background binding to bovine serum albumin (BSA). b-c, Mutation frequencies (number of mutations per 233 length of V-gene) of b, anti-RBD and S1, and c, anti-S2 binding rmAbs from (a). High binding rmAbs are 234 defined as positive for double-barcoded tetramer binding and AUC >3. d, Neutralization curves for rmAbs

RBD-3, RBD-4, RBD-14, and RBD11, blocking Wuhan-Hu-1 pseudovirus and variants Alpha+E484K,
beta, gamma, epsilon, and delta. e-f, Heatmaps indicating e, IC50 (ng/ml) for each rmAb (e) and f, NT50
(reciprocal dilution) of D28 plasma of n=9 individuals to the indicated pseudovirus variants. *****P* <0.0001
according to unpaired two-tailed t-test.

239

240 were included (Extended Data Table 3) — variants alpha+E484K (B.1.1.7+E484K; N501Y, 241 E484K), beta (B.1.351; N501Y, K417N), and gamma (P.1; N501Y, K417T) share a similar set 242 of RBD mutations, of which N501Y contributes most to immune escape²⁶. A different mutation, 243 L452R, is shared by delta (B.1.617.2; L452R, T478K) and epsilon (B.1.429; L452R), and also 244 promotes escape from antibody neutralization²⁷. Each variant can be neutralized by at least four 245 of the ten rmAbs, highlighting the vaccine's potency to generate at least partial protection to all 246 variants (Fig. 4d,e, Extended Data Fig. 11). Antibody neutralization follows RBD mutations, as 247 antibodies tend to block either alpha, beta, and gamma (N501Y), or delta and epsilon (L452R). Two antibodies (RBD-8 and RBD-11) were broadly neutralizing against all variants. Plasma 248 249 neutralizations showed significantly lower potency against variants than against Wuhan-Hu-1 in 250 all patients, while trending to a better neutralization of delta and epsilon than of alpha, beta, and 251 gamma (Fig. 4f). Interestingly, while the plasma of individual P6 showed very limited 252 neutralization efficacy to alpha, gamma, and delta, we show that P6 had potent neutralizing B 253 cell clones against all variants. P6, therefore, will likely have an extended level of protection 254 from a recall memory B cell response post vaccine, which is inaccessible to assessment by 255 measuring plasma neutralization.

256

257 Discussion

Our study provides a detailed characterization of the B cell response to the BNT162b2 mRNA vaccine on a single-cell level. Parsing the anti-S1 and S2 responses provides important insights into why the second vaccine dose is vital for protection. Our results demonstrate that the first vaccine dose activates a non-neutralizing recall response predominantly targeting epitopes in the S2 protein subunit, which is conserved across human-pathogenic coronaviruses^{22,23}, while the second vaccine dose is vital to boosting neutralizing B cell responses to S1 and RBD.

264 The vaccination induces two major shifts in distinct B cell subtypes: (i) activation of 265 UM and their differentiation into RSM, and (ii) activation and expansion of S antigen-specific 266 PB and ASM. UM are thought to develop independently of the GC reaction, and possess a polyreactive repertoire for rapid B cell responses²⁸. UM are broadly activated early after 267 vaccination, consistent with a natural or 'innate-like' B cell response. The unchanged mutation 268 269 frequency post differentiation indicates a GC-independent response. Once switched, activation 270 levels in RSM decrease, indicating that they are not further promoting an activated B cell 271 response.

In contrast, the antigen-specific PB and ASM response is likely derived from GCdependent processes. The first vaccination induces an IgA-dominant PB response against S2 with high mutation frequencies, which is cross-reactive to the human-pathogenic betacoronaviruses OC43 and HKU1. Our data are consistent with a recall response of mucosal memory B cells that matured during prior pulmonary coronavirus infections.

277 After this initial response, we observed an influx of minimally mutated ASM on D21 and 278 D28, which target S1 and RBD. We show that low mutation frequency corresponds to high 279 affinity against RBD. mRNA vaccines have been shown to induce robust and prolonged GC reactions, with PB and SM persisting in GC for over three months^{29,30}. Despite their low 280 281 mutation frequency, the delayed development and the switched phenotype of S1/RBD-specific 282 PB and ASM indicate that they underwent GC maturation. High BCR affinity and a naïve phenotype foster preferential recruitment into GC^{31-33} and high affinity also promotes release 283 from the GC as PB, plasma cells, or memory B cells³⁴. High affinity of minimally mutated BCRs 284 could therefore limit GC maturation to a relatively short time frame. 285

286 We utilized plasma samples and our low mutation RBD-binding rmAbs to characterize 287 neutralization against several SARS-CoV-2 variants of concern. While we found a significant 288 degree of immune escape, we also identified antibodies with neutralization potency against each 289 variant. Importantly, we observed potent neutralization activity against the highly infectious 290 delta variant, which has quickly become the dominant strain world-wide. Delta-neutralizing B 291 cells were even found in an individual with very limited plasma neutralization potency, fueling 292 hope that even individuals with low neutralizing titers can raise a recall memory response upon 293 infection with delta.

- 294 Together, our study provides a detailed characterization of the blood B cell response to
- the BNT162b2 mRNA vaccine. Our data emphasize the importance of the second vaccine dose
- in inducing generation of anti-S1 RBD antibodies that contribute to neutralization of SARS-
- 297 CoV-2 variants, including delta.

298 Figure legends

Fig. 1: Single cell transcriptomic analysis of the B cell response following BNT162b2

300 vaccination. a, Outline of experimental approach. b, UMAP visualization of single-cell B cell

301 transcriptome sequencing data of all individuals at four timepoints. B cell cluster assignments are

- 302 based on gene expression and cell surface expression (CITE-seq) of canonical B cell markers. c,
- 303 Mean percentages of B cell subtypes shown in (b). d, Individual and mean percentages of B cell
- 304 types in (b) at four timepoints. *n*=9 individuals at all timepoints. Individual values, means and
- standard deviations are shown. **P < 0.01, ***P < 0.001, ****P < 0.0001 according to two-tailed
- 306 one-way ANOVA test in comparison to the first timepoint.

Fig. 2: Unswitched memory B cell differentiation and expansion of IgG⁺ plasmablasts in

308 response to vaccination. a, Alluvial plot of B cell trajectories (left) across timepoints and

309 UMAP projection (right) of clonally expanded B cells that are related to at least one UM at D0.

310 Clonal expansions included have \geq 3 members at \geq 2 timepoints. **b-c**, Gene expression in UM (**b**)

- and RSM (c) of genes involved in B cell signaling and activation. d, Alluvial plot of B cell
- 312 trajectories (left) and UMAP projection (right) of clonally expanded B cells that are related to at

least one PB at D28. Clonal expansions included have ≥ 3 members at ≥ 2 timepoints. **e**, Gene

314 expressions of activation markers in PB. **f**, Percentage of IgG^+ PB per individual (n=9), at four

315 timepoints. g, Average mutation frequency of $IgG^+ PB$ per individual (*n*=9) at four timepoints.

316 Individual values, means and standard deviations are shown. *P < 0.05; or **P < 0.01 according

to two-tailed one-way ANOVA test in comparison to the first timepoint.

318 Fig. 3: Vaccination induces a IgA⁺ anti-S2 response on day 7 followed by IgG⁺ RBD

319 response on days 21 and 28. a-c, Quantification of flow cytometry data, showing percentages of

320 a, anti-S PB, and **b**, anti-S SM in all B cells at four timepoints. **c**, Percentage of IgG⁺ anti-S SM

in all anti-S SM at four timepoints. . *n*=9 individuals per timepoint. Individual data points are

- 322 averages of two independent experiments. d, UMAP visualization of demultiplexed
- 323 transcriptomic data of anti- S^+ and anti- S^- sorted B cells, showing cluster assignments of memory
- 324 (blue), activated memory (turquoise), and PB (red) (left) and antigen-specificity to S2 (orange),
- 325 RBD (green), and S1n (blue) (right). e-h, Proportions of sorted cells shown in (d), separated by
- 326 antigen and by e, cluster distribution, f, timepoint, g, clonality, and h, isotype. i, Plasma IgG
- 327 levels against S2 (left), RBD (center), and S1 (right) for n=9 individuals at four timepoints. AUC

328 for plasma dilutions are shown. j, Plasma neutralization curves (left) and quantification (NT50)

329 of neutralization titers (right) of n=9 individuals at timepoints post vaccination. k, V-gene

330 mutation frequencies (number of mutations per length of V-gene) of B cells specific for S2 (left),

- **331** RBD (center), and S1n (right) at timepoints post vaccination. Dashed line indicates the average
- 332 mutation frequency of sorted antigen negative B cells. Individual data points represent single B
- cells from n=9 individuals. Means and standard deviations are shown. *P < 0.05, **P < 0.01,

P < 0.001, *P < 0.0001 according to two-tailed one-way ANOVA test in comparison to the

335 first timepoint displayed and g-j, chi-square test.

336 Fig. 4: Neutralization of SARS-CoV-2 pseudovirus and variants by BNT162b2-induced

antibodies. a, recombinant mAbs derived from BNT162b2-induced B cells bind S2, S1 RBD,

and S1.Two-column heatmaps show barcoded tetramer sequencing data (PE and APC labeled)

represented as centered log ratio transformed (CLR) counts. Bar graphs show binding of rmAbs

340 generated from the corresponding B cells, represented as area under the curve (AUC) of serial

341 dilutions, measured by ELISA. Threshold, represented as 0, was set to the average binding to

342 BSA plus three times the standard deviation of background binding to bovine serum albumin

343 (BSA). b-c, Mutation frequencies (number of mutations per length of V-gene) of b, anti-RBD

and S1, and c, anti-S2 binding rmAbs from (a). High binding rmAbs are defined as positive for

- double-barcoded tetramer binding and AUC >3. d, Neutralization curves for rmAbs RBD-3,
- RBD-4, RBD-14, and RBD11, blocking Wuhan-Hu-1 pseudovirus and variants Alpha+E484K,
- 347 beta, gamma, epsilon, and delta. e-f, Heatmaps indicating e, IC50 (ng/ml) for each rmAb (e) and
- **348 f**, NT50 (reciprocal dilution) of D28 plasma of n=9 individuals to the indicated pseudovirus

349 variants. ****P < 0.0001 according to unpaired two-tailed t-test.



Extended Data Figure 1: Classification of UMAP B cell clusters. a, Distribution of B cell
 clusters for each individual (n=9) included in the study. b, Gene and cell surface expression of B

353 cell clusters, represented as heatmap / dot plots. c, UMAP embedding of B cells colored by 354 CD19, CD38, IgD, and CD27 protein expression (blue). d, UMAP embedding of naïve B cells 355 colored by CD38 protein expression (blue), and CD24 gene expression (red). e, UMAP 356 embedding of memory B cells colored by CD86 and PTPN6 gene expression (red). f, Average 357 proportions of isotype subclasses in each B cell cluster in *n*=9 individuals vaccinated individuals 358 across all timepoints. g, Average combined mutation frequency (number of mutations per length 359 of V-gene) in light chain and heavy chain V-gene regions in n=9 individuals in the respective 360 nine different B cell clusters. Individual values, means, and standard deviations are shown.



362 Extended Data Figure 2: Characterization of clonal B cell expansions in response to mRNA vaccination. a, Cells corresponding to clonal expansions shown in (Fig 2a). Number of cells in 363 364 each clonal expansion (n=106) in each B cell cluster at all four timepoints. Statistics are not 365 calculated for D0 as each clonal family is set to contain at least one clone at D0 in the UM B cell 366 cluster. b, Average mutation frequency (number of mutations per length of V-gene) of clonal 367 UM expansions at D0 and clonal RSM expansions at D7, D21, and D28. Each dot represents the 368 average of each mutation frequency for the clonal family in specified B cell clusters and time. c, 369 Cells corresponding to the clonal expansions shown in (Fig. 2d). Number of cells in each clonal

- 370 expansion (n=52) in each B cell cluster at all four timepoints. Statistics are not calculated for
- 371 D28 as each clonal family is set to contain at least one clone at D28 in the PB cluster. Individual
- values, and **a**,**c**, standard error of the means, and **b**, standard deviations are shown. **P < 0.01,
- 373 ***P<0.001, ****P<0.0001 according to **a,c**, two-tailed Kruskal-Wallis test and **b**, paired two-
- tailed t test.

375



376 Extended Data Figure 3: Pathway enrichments and differentially expressed genes in

377 response to mRNA vaccination. a-c, Gene enrichment signatures of DEGs via Metascape³⁵ in

- a, UM, b, RSM, and c, PB for D7 (yellow dots), D21 (turquoise dots), D28 (red dots) versus pre-
- 379 vaccination. Dashed line represents q < 0.01. **d**,**e**, Volcano plot of differentially expressed genes
- in d, USM and e, RSM at timepoints D7 (left), D21 (center), and D28 (right) relative to D0.



382 Extended Data Figure 4: Global PB proportions measured by flow cytometry and scRNA-

383 Seq. a,b, Flow cytometry data, a, mean percentages of PB in all B cells at the four indicated

- timepoints. **b**, Proportions of IgG^+ (left), IgA^+ (center), and IgM^+ PB (right) of all PB. **c-e**,
- 385 scRNA-Seq data, proportions of **c**, IgG subclasses, **d**, IgA subclasses, and **e**, IgM in total PB.
- 386 n=9 individual values, means, standard deviations are shown. *P < 0.05, **P < 0.01,

381

387 ***P < 0.001, ****P < 0.0001, or exact value according to two-tailed one-way ANOVA test.



388



390 Gating strategy for sorting on live singlet SM and PB based on marker expression: CD3⁻, Cd19⁺,

- 391 IgD⁻, IgM⁻, CD27⁺. Cells were stained with two antigen-tetramers for each subunit of S (S1, S2,
- and RBD), respectively, labeled with PE and APC. Double-positive cells were sorted. b,
- 393 Representative flow cytometry plots of S+ PB. c, Proportion of IgA^+ (left) and IgG^+ (right) S⁺
- 394 PB in all S^+ PB at the indicated timepoints post vaccination. **d**, Representative flow cytometry

- 395 plots of S^+ SM. **e**, Proportion of IgA⁺ S⁺ SM in all S⁺ SM at the indicated timepoints post
- 396 vaccination. **f**, Dot plots of gene expression of B cell clusters shown in (**Fig. 3d**). **c**,**e**, n=9
- individual values, means, and standard deviations are shown. *P < 0.05, **P < 0.01, ***P < 0.001
- 398 according to two-tailed one-way ANOVA test.



400 Extended Data Figure 6: Specific binding of S antigen tetramers to sorted cells. a-d, Single-

- 401 cell sequencing data analysis of barcodes in de-multiplexed data set. Antigen-positive and
- 402 negative CD3⁻, Cd19⁺, IgD⁻, IgM⁻, CD27⁺ B cells were mixed during the sort. **a**, Heatmap of
- 403 centered log ratio transformed (CLR) counts of barcoded PE and APC tetramers with S2, RBD,
- 404 and S1 for all sorted cells. Inset magnifies the antigen-specific cells used in the analysis. **b**,
- 405 Correlation of barcoded PE and APC tetramers S2 (top), RBD (middle), and S1 (bottom). c,
- 406 Correlation of barcoded APC tetramers of S1 and RBD. d, Correlation of barcoded APC
- 407 tetramers of S2 and RBD.



409 Extended Data Figure 7: Plasma reactivity to S protein subunits. a, Area under the curve

- 410 (AUC) for anti-S2 IgA (left), anti-RBD IgA (center), and anti-S1 IgA (right) from n=9
- 411 vaccinated individual plasma samples. **b-d**, Plasma IgG (left) and IgA (right) reactivity to **a**, S2,
- **b**, RBD, **c**, S1 as determined by ELISA. Graph shows optical density units at 450nm of serial
- 413 plasma dilutions. *P < 0.05, **P < 0.01, ***P < 0.001, according to two-tailed one-way ANOVA
- 414 test.



415

416 Extended Data Figure 8: Analysis of individual P1 who contracted COVID-19 eight weeks

417 post second vaccination. a-b, Plasma reactivities of a, IgG and b, IgA to RBD as measured by

418 ELISA in serial plasma dilutions (right) and depicted as AUC (left). c, Plasma neutralization

419 titers (left) and neutralization curves for plasma of individual P1 at D7, D21, D28 (right). **d**,

420 Plasma reactivities to RBD for IgG (left) and IgA (right), on D28 compared to day 120 (D120),

421 two weeks after COVID-19 diagnosis. P1 is highlighted in red, the other eight individuals are

422 grey. *P < 0.05, **P < 0.01, ***P < 0.001 according to **a-c**, two-tailed one-way ANOVA test and

423 **d**, paired t-test.



425 Extended Data Figure 9: Binding affinities of anti-RBD, S1n, and S2 rmAbs. a-c, rmAb-

- 426 antigen interaction intensities were measured by bio-layer interferometry with immobilized onto
- 427 Octet sensors, and S protein subunits. **a**, RBD, **b**, S1n, and **c**, S2 in solution. Binding curves are
- 428 shown for the indicated concentrations of antigen. d, Kd values of antibodies shown in a-c.







431 coronavirus S proteins. a, Binding of anti-S2 and anti-RBD rmAbs to SARS-CoV-2 S2, SARS-

432 CoV-2 RBD, HCoV-OC43 spike, and HCoV-HKU1 spike, assessed by ELISA and represented

433 as AUC of optical density measurements of serial dilutions. No binding was observed for HCoV-

- 434 229E and HCoV-NL63 spike proteins. Threshold, represented as 0, was set to the average
- 435 binding to BSA plus three times the standard deviation of background binding to BSA.



436

437 Extended Data Figure 11: Neutralization of SARS-CoV-2 Wuhan-Hu-1 pseudovirus and

438 variants by rmAbs from vaccinated individuals. a, Neutralization curves for each selected

439 rmAb against the five strains, measured by luminescence measurement upon SARS-CoV-2

- 440 pseudoviruses infection of transgenic HeLa cells expressing human ACE2. Pseudovirus strains:
- 441 Wuhan-Hu-1, Alpha+E484K, Beta, Gamma, Epsilon, and Delta.

					Symptoms of BNT162b2		Site of v	accination	Confirmed SAR	S-CoV-2 infection	Symptoms to SARS-
Participant	Age	Sex	Race	Ethnicity	Dose 1	Dose 2	Dose 1 (site)	Dose 2 (site)	Prior	Post	CoV-2 infection
P1	36-40	м	Caucasian	Hispanic	Site tenderness	Site tenderness	Left	Left	No	Yes	Loss of smell, muscle aches, and fatigue
P2	21-25	м	Asian	Not Hispanic	Site tenderness	Fever, muscle aches, fatigue, chills	Left	Left	Νο	No	N/A
Р3	31-35	м	Asian	Not Hispanic	Site tenderness, muscle aches	Site tenderness, muscle aches, headache, chills	Left	Left	No	No	N/A
P4	26-30	м	Asian	Not Hispanic	None	Site tenderness, fever, muscle aches, fatigue, chills, loss of appetite	Left	Left	No	No	N/A
Р5	31-35	F	Asian	Not Hispanic	Site tenderness	Site tenderness, muscle aches, fatigue, headache	Right	Right	No	No	N/A
P6	46-50	F	Caucasian	Not Hispanic	Site tenderness, site swelling	Site tenderness	Left	Left	No	No	N/A
P7	51-55	F	Asian	Not Hispanic	Site tenderness, muscle aches, fatigue, headache, joint pain	Site tenderness, muscle aches, fatigue, headache, joint pain, fever, chills	Right	Right	Νο	No	N/A
P8	26-30	F	Caucasian	Not Hispanic	Site tenderness	Site tenderness, site swelling, muscle aches, fatigue, headache	Left	Left	No	No	N/A
P9	36-40	м	Caucasian	Not Hispanic	None	None	Right	Right	No	No	N/A

Extended Data Table 1. Characteristics of participants in BNT162b2 vaccination study.

variant	greek alphabet				RBD mutations
name	name	Classification	origin	mutations	(319-541)
B.1.1.7 +		Variant of		Δ69/70, Δ144, E484K, N501Y, A570D,	
484K	Alpha + 484K	Concern	UK	D614G, P681H, T716I, S982A, D1118H	E484K, N501Y
		Variant of	South	D80A, D215G, Δ241/242/243, K417N,	K417N, E484K,
B.1.351	Beta	Concern	Africa	E484K, N501Y, D614G, A701V	N501Y,
		Variant of	Japan /	L18F, T20N, P26S, D138Y, R190S, K417T,	K417T, E484K,
P1	Gamma	Concern	Brazil	E484K, N501Y, D614G, H655Y, T1027I	N501Y,
		Variant of		T19R, T95I, G142D, Δ156/157, R158G,	
B.1.617.2	Delta	Concern	India	L452R, T478K, D614G, P681R, D950N	L452R, T478K
		Variant of	US /	S13I, W152C, L452R, D614G	L452R
B.1.429	Epsilon	Interest	California		

Extended Data Table 2. SARS-CoV-2 pseudovirus variants used in neutralization assays.

Extended Data Table 3. Expressed rmAbs derived from S⁺ sorted B cells

Antibody ID	Participant	Timenoint		
Antibody ib		Timepoint	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQG	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQL
RBD-1	P6	D28	LEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRS DDTAVYYCARDFGGIAAAIVSSSRGFDYWGQGTLVTVSS	PGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAE DEADYYCQSYDSSLSRWVFGGGTKLTVL
			EMQLVESGGGLIQPGGSLRLSCAASGLIVSNNYMNWVRQAPGKG LEWVSVLYPGGTTYYADSVKGRFTISRDNSKNTLFLQMNSLRAED	DIQMTQSPSSLSASVGDRVTITCQASEDISKYLNWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDLA
RBD-10	P2	D28	AAMYYCAREGRGGAFDIWGRGTMVTVSS	TYYCLQYDNLPRYTFGQGTKLEIT
RBD-11	P1	D28	QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGNYYWSWIRQPPGK GLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADT AVYYCARSLRYFDWLAERGDWFDPWGQGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLLIYDASNRATGIPARFSGSGSGSGTDFTLTISSLEPEDFA VYYCQQRSNLFTFGPGTKVDIK
RBD-12	P5	D28	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQG LEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSE DTAVYYCARGLVVPAAKGDLDYWGQGTLVTVSS	EIVMTQSPATLSVSPGEGATLSCRASQSVSSNLAWYQQKPG QAPRLLIYGASTRATGIPARFSGSGSGSGTEFTLTISSLQSEDFA VYYCQQYNNWLYTFGQGTKLEIK
RBD-13	P7	D28	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKG LEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGD TAVYYCARVLYYYDSSGYYKRIYWYFDLWGRGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPG KAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQSYSTPPWTFGQGTKVEIK
RBD-14	P6	D28	QVQLVESGGGVVQPGRSLRLSCAASGFTFSMHWVRQAPGKGLE WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDT AVYYCAREVSGSGWPIDYWGQGTLVTVSS	SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQ APVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEA DYYCQVWDSSSEDYVFGTGTKVTVL

RBD-15	P2	D28	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYVDSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCARNFWFGDEGYFDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPG QAPRLLIYGASTRATGIPARFSGSGSGSGTEFTLTISSLQSEDFA VYYCQQYNNWPPYTFGQGTKLEIK
RBD-16	P9	D28	EIKLVQSGGGSVQPGGSLRLSCAASGFTFSAYWMHWVRQVPGKE PVWVSRIHGDAETTTYVDSVKGRFTISRDNAKNTLYLQMNSLRVD DTAVYYCARDRLSFYSGRHTNSDAFEVWGQGTTVTVSS	HSVLTQAPSVSAAPGQKVTISCSGNNSNIGNNFVSWYQQFP GTAPKLLIYENDKRPSGIPDRFSGSKSGTSATLGITGLQTGD EAFYYCGTWDSSLSTGRVFGGGTKLTVL
RBD-17	P4	D28	QVQLVQSGSELKKPGASVKVSCKTSGYPFSTYAMNWVRQAPGQG LEWMGWINTNTGNPTYAQGFRGRFVFSLDTSVSTAYLQISSLKAE DTGVYYCARSRTYYYDRSGYPQDSWGQGTLVTVSS	DTEMTQSPDSLAVSLGERATITCKSSHSLLYSSTNKNNLAW YQQRPGQPPRLLIYWASTREFGVPDRFSGGGSGTDFTLTIS SLQAEDVAVYYCQQYYNTPPTFGQGTKVEIK
RBD-18	P7	D7	EVQLLQSGGQSVRPGGSLRLSCVASGFNFHDYAMSWVRAPPGK GLEWVATITGGGTITHYADSLKGRVTISRDISTSTIFLHFHNVRVEDA ALYYCAKVQYQLWLSPFDHWGQGSPVAVSS	SYDLTQSSSLSVSVGQTATITCSGSKVGQYYTSWYRKKLGQ PPILIIYQNDRRPSEIPDRFSGSTSGNIASLTITGTHPLDAADY YCQSSDSYNVVFGGGTTLAVL
RBD-19	P6	D21	QVQLQESGPGVVKPSGTLSLTCTVSGYSIRDGYFWGWVRQPSGK GLEWIGSVYHSGTTYYNPSLKSRLTISVDTSKNQFSLDLSSVTAAD TALYYCARGHSSVGNDYWGQGALVTVSS	QSALTQPASVSGSPGQSITISCTGSSSDVGDSDLVSWYQKY PGKAPKLIIYEVNKRPSGVSNRFFGSKSGDTASLTIFGLQAE DEADYYCYSHAGSSTWMFGGGTKLTVL
RBD-2	P6	D21	QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQG LEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDT AVYYCARGVVGATPGYFDYWGQGTLVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPG QAPRLLIYGASTRATGIPARFSGSGSGSGTEFTLTISSLQSEDFA VYYCQQYNNWLTFGGGTKVEIK
RBD-20	P7	D7	QVQLVQSGSGVKKPGASVRVSCIASGYPFSGYALHWLRQAPGQS LEWMGWINGGNGNSKYSQNFEGRVILSRDTSATIVYMDLTSLRSE DTAMYYCARGRAHCNNDGCSWGSDYFDCWGQGTLVTVSS	ESVLTQSPGTLSLSPGERATLSCRASQTIRNNYLAWYQQKP GQTPILLIYGASSRATGIPDRFIGSGSGTDFTLTISRLEPEDFA MYYCQQYGASPMYTFGQGTKLEIK
RBD-21	P9	D28	QITLKESGPALVQPTQTLALTCTFSGFSLTSGGLAVGWIRQPPGQA HQWLALVYWDDTKRFNPSLESRLTITKDTSKNQVVLTMTNMDPVD TGTYYCAHSTGDGYFDDWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQSIYNFLNWYQQKPG KAPKLLIYAASSLQSGVPSRFSGSGSGTEFILSISSLQPEDSA TFFCQQSYNVPYTFGQGTKLEIK
RBD-22	P9	D7	EVQLVETGGGLIQPGGSLRLSCAASGFTGSDNYMSWVRQAPGKG LEWVALIYIGGSTVYADSVKGRFTISRDSSKNTLYLQMNTLRVEDTA VYYCARDQGEDGYYKDAYDIWGQGTMVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQTITTYLNWYQQKPGK APKLLIYAASALESGVPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQSYSIPHMFGQGTKVEIK
RBD-23	P7	D28	EVQLLQSGGQSVRPGGSLRLSCVASGFNFHDYAMSWVRAPPGK GLEWVATISGGGTVTHYADSVKGRVTISRDISTSTIFLQFNNVKVED AALYYCAKVQYQLWLSPFDHWGQGSPVAVSS	SYDLTQSSSLSVSVGQTATITCSGSKVAQYYTSWYQKKLGQ PPVLIIYQNDRRPSDIPDRFSGSTSGNIASLTITGTQPLDAAD YYCQSSDSYDVIFGGGTTLAVL
RBD-24	P8	D28	QLQLQESGPGLVKPSETLSLTCSVSGGSISRGSYYSGWIRQSPGK GLEWIGNIYYDGYTYYNPSLKSRVTMSIDTSKNQFSLQLRSVTAAD TALYYCARAHGPGPPGIAAAANWYFDLWGRGTLVTVSS	SYVLTQPPSVSVAPGQTARITCGGDDIDTESVHWYQQRPG QAPVLVVYDDTDRPSGIPERFSGSNSGDTATLTISRVEGGD EADYYCHVWDSNSNHVVFGGGTKLTVL
RBD-25	P8	D7	QVQLVESGGGVVQPGRSLRLSCVASGFTLSNYLIHWVRQAPGKGL EWVAVVSNDGRNEYYADSVKGRLTVSRDSSRQTLYLQMNSLRAE DTAVYYCAREGMSVTHDGFDIWGQGTMVTVSS	QAGLTQPPSVSKGLRQTATLTCTGNSNNVGDQGAAWLQQH QGHPPKLLSYRDNNRPSGISERFSASRSGNTASLTITGLHPE DEADYYCSAWDSSLSAWVFGGGTKVTVL
RBD-26	P8	D7	EVQLVESGGGLVQPGRSLRLSCAASGFTFDNYAMHWVRQVPGKG LQWISGIAWNSGSVGYADSVNGRFTISRDNAKNSLYLQMNSLRRE DTAFYYCAKDFYPLYYGSGIDWYFDLWGRGTLVTVSS	QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNNVNWYQQLP GTAPKLLIYSNNQRPSGVPDRFSGSKSDTSASLAISGLQSED EADYYCAAWDDSLKGGVFGGGTKLTVL
RBD-27	P4	D28	AVQLVESGGGLVKPGGSLTLSCAASGFAFSDTWMSWVRQAPGKG LEWVGRIKSNTDGGTTAYAAPVQGRFTISRDDSKNTLYLQVNSLKT EDTAVYFCATDGGGIHLTWGQGTLVTVSS	ENVLTQSPATLSLSPGERATLSCGASQSVSSNYLAWYQQKP GLAPRLLIYDASSRATGIPDRFSGSGSGTDFTLSISRLEPEDF ALYYCQQYGSSPVTFGGGTKVEIK
RBD-28	P6	D7	LGQLVQSGGEVRKPGASVKVSCKASGYTFTETGIIWVRQAPGQGL EWMGWISNYNGNTKSAEKFQGRITMTTDTSTTTASMELTGLTSDD TAVYYCATKHARTGGVTGNWFDTWGQGTLVTVSS	QSALTQPRSVSGSPGQAITISCTGASTDVGRYNYVSWYQQL PGKPPKLVIYDVNERPSGVPLRFSGSKSGNTASLTISAVQAE DEADYYCCSYAGSYIFVFGSGTRVTVL

RBD-29	P8	D21	QVLLVESGGGWVKPGGSLRLSCAASGFNFSDFYMTWMRQAPGK GLEWVSTLSASSSSVYYADSVRGRFTISRDNAKESVYLHMNTLRP EDMAIYYCARGDI DYWGOGTI VTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHRDGNTYLNWF HQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSDTDFTLKISR VEAEDVGVYYCMQGTHWPPI FTEGPGTKI DIK
RBD-3	P6	D28	QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGL EWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAV YYCARPFRYDSGSYWDHAFDIWGQGTMVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQL PGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAE DEADYYCQSYDSSLSGWEVFGGGTKLTVL
RBD-30	P4	D21	EVQLVESGGGLVQPGGSLRLSCVASGFTFGNHWTNWVRQAPGK GLEWVANMKEDGSIKYYVDSVKGRFTISTDNAKNSLYLQMNSLRD EDTAVYYCARESSYETTTIFTGFEIWGQGTMVTVSS	QAGLTQPPSVSKDLGQTATLTCTGDTNNVGDRGATWLQQY QGHPPKLLSYRNNNRPSGISERLSASRSGKTASLTITRLQPE DEADYYCSAWDSSLSVWVFGGGTKLTVL
RBD-4	P6	D28	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGHG LEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRS EDTAVYYCARGGRYCSSTNCYSHVGIVDWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPG KAPKRLIFPASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDF ATYYCLQHNNYPLTFGGGTKVEIK
RBD-5	P8	D21	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKG LEWVSGISWNSGSVGYADSVKGRFTISRDNAKNSLFLQMNSLRAE DTALYYCAKDIGSGYGDYFDYWGQGTLVTVSS	SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQ APVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEA DYYCQVWHSSSDHYVFGTGTKVTVL
RBD-6	P1	D28	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGK GLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCAKMGGPYCSGGSCYSGYFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIA TYYCQQYDNLPQTFGGGTKVEIK
RBD-7	P6	D28	QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGK GLEWIGTIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADT AVYYCARRPLRHDSSGYLFDYWGQGTLVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQL PGTAPKLLIFVNSNRPSGVPDRFSGSKSGTSASLAITGLQAE DEADYYCQSYDSSLSDVVFGGGTKLTVL
RBD-8	P1	D28	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCARDGVTITMVRGVIGPAFDIWGQGTMVTVSS	DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSGSGTDFTFTISSLQPEDIA TYYCQQYDNLPYTFGQGTKLEIK
RBD-9	P2	D28	QVQLQESGPGLVKASQTLSLTCTVSGGSISSGGYYWSWIRQHPGK GLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLRSVTAADT AVYYCARDYGGNSNYFDYWGQGSLVSVSS	DIQMTQSPSSLSASVGDRVTITCQASQDITNYLSWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSGSGTDFTFTISSLQPEDIA TYYCQQYHNLPLTFGGGTKVEIK
S1n-1	P2	D28	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPLHWVRQAPGKG LEWVAVISYDGSNKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAED TAVYYCARDGSGSGAFDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQH PGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQA EDEADYYCSSYTSSSTWVFGGGTKLTVL
S1n-2	P4	D21	QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGK GLEWIGEIYHSGNTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADT AVYYCARRSSASSGWSPSLFDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQH PGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQA EDEADYYCFSYAGSSTWVFGGGTKLTVL
S1n-3	P7	D28	QVQLQESGPGLVKPSETLSLTCTVSAYSISSGYYWGWIRQPPGKG LEWIGNIYHSGNTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTA VYYCARDLRIVVVVAAAYYFDYWGQGTLVTVSS	QSALTQPASVSGSPGQSITISCTGTSSDVGSYNLVSWYQQH PGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQA EDEADYYCCSYAGSTLYVFGTGTKVTVL
S1n-4	P7	D7	EVRLVESGGGLVEPGGSLRLSCAASGFTFVVHSMNWVRQAPGKG LEFVASISRNLDYIDYADSVKGRFTISRDNAKNSVFLQMNRLRGED TARYYCVRGDSSSWHLFDYWGQGMLVTVSS	EVVLTQSPDTLSLSPGERAILSCKASQSVGNYLAWYQQQPG QVPRLLIYGPSSRATGIPDRFSGGGSGTDFTLTISRLEPEDFA IYYCHQYGYSPWAFGPGTKVEIK
S1n-5	P9	D28	EVQLVESGGGLVQPGRSLRLSCRASGFTFGDYAINWVRQAPGKG LEWVGFIRNEAYGGTTDYAASVKGRFTISRDDSNSIAYLQMNSLTT GDTALYYCTRNECPFGACTTHALDPWGLGTLVTVSS	EIVMTQSPLSLSVTPGEPASISCRSSQTLLYTNGNNYLDWYL QKPGQSPQLLIYLASKRASGVPDRFSGSGSGTDFILKISRVE AEDVGVYYCMQALQAPTFGQGTRLEIK
S1n-6	P6	D28	EVQLVESGGGLVRPGGSLRLSCAASGFTFSSYSMNWVRQAPGKG LEWVSSISSSTSYIHYADSVKGRFTISRDNARNSLFLQMNSLRAED TAVYYCARDLSNSWYNPHYFDSWGQGTLVTVSS	EIVLTQSPGTLSLSPGERATLSCRASQSVSNNFLAWYQQKP GQAPRLLIYGASSRATGIPDRFSGRGSGTGFTLTISRLEPED FAVYYCQQYGDSPRSFGPGTKVELK

S2-1	P9	D7	EVQLVESGGDSVQPGGSLRLSCAASGFTFSNYWVHWVRQAPGK GLVWVSRIREDGIFTTYADSVKGRFTISRDNARNTVSLQMNSLRAE DSAVYYCVRVKVDADLVTADYWGQGTRVTVSS	QTVVTQEPSLTVSPGGTVTLTCASSTGAVTSDFYPNWFQQK PGQAPRALIYSTSNKHSWTPARFSGSLLGGKAALTLSGAQP EDEAEYFCLLYYGGAYVFGGTYVFGTGTKVTVL
S2-10	P4	D7	EVQLVQSGAEVKEPGESLKISCKGSGYSFSTYWIGWVRQLPGKGL QWMGLIYPDDSDTRSNPTFQGQVTMSVDKSTDTAYLQWSSLKAS DTAMYFCARRYCPDTNCYLAAFDLWGQGTMVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSDVGSYDYVSWYQQ HPGKAPRLMIYDVTKRPSGVPARFSGSKSGNTASLTISGLRA EDEGHYYCCSYAGRHIYEVFGGGTKLTVL
S2-11	P2	D28	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYVDSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCARVSSGSYYGQLDYWGQGTLVTVSS	EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQ SPKLLIKYASQSISGVPSRFSGSGSGTDFTLTINSLEAEDAAA YYCHQSSSLPQTFGQGTKVEIK
S2-12	P7	D28	EVQLVQSGAEVKKPGESLEISCKASGYNFTNYYIGWVRQMPGKGL EWMGIVYPGDSDTRYSPSFQGQVTISADKSITTAYLRWRSLKASDT AMYYCARRQYYETDSYYPAAFDIWGQGTMVTVSS	DIQMTQSPSSLSASVGERVTITCRASQSISTYLNWYQQKPG KAPKLLIYAASSLQIGVPSRFSGSGSGTAFTLTISSLQPEDFA TYYCQQSYTTPWTFGPGTKVEIK
S2-13	P7	D28	QVQLVQSGAELKKPGASVKVSCKASGYTFSNFYIHWVRQAPGQG LEWMGRINPIIGSTVYAQKFQGRVTMTRDTSTSTIYIELIGLRSEDTA LYYCGKEHDATVAAGGMEGGLDHWGQGSLVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNFVSWYQQ HPGKAPKLMIYDVTKRPSGVPYRFSGSKSGNTASLTMSGLQ PEDEADYYCCSYAGRYTWVFGGGTKLTVL
S2-14	P7	D7	QVQLVQSGAEVKKPGASVRVSCKASGYTFSSFYIHWVRQAPGQG LEWMGRINPIIGSTVYAQKFQGRVTMTRDTSTNTVYIELSSLTSEDT ALYYCGKEHDATVAEGGMEGGLDHWGQGTLVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNFVSWYQQ HPGKAPKLMIYDVNKRPSGVPYRFSGSKSGNTASLTMSGLQ PEDEADYYCCSYAGRYTWVFGGGTKLTVL
S2-2	P4	D7	QVQLQESGPGLVKPSGTLSLTCTVSGGSINISNWWIWVRQSPGKG LEWIGEIYHGGNTNYNPSLKSRVSISVDKSKNQFSLSLSSVTAADTA VYYCARAMRTENSFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRVTFTCRASQSINIYLSWYQQRPG KAPKLLIYGAFNLQNGVPSRFSGSGSGTDFTLTITNLQPEDF ATYYCQQTYNIPFTFGPGTKVDIK
S2-3	P5	D7	QVQLRESGPGLVLPSQTLSLTCTVSGGSISTEGYYWTWIRQHPGR GLEWIGYIYYSGSAYYNPSLKSRVTISIDTSENQFSLRLRSVTAADT ALYFCARDDRLAPIVRGAFDIWGQGRMVTVSS	EIVLTQSPGILSLSPGERATLSCRASESVGSSFLAWYQQKPG QAPRLLMYGASYRATGIPDRFSGSGSGTDFTLTIRRLEAEDF AVYYCQQYGSSPASFGQGTKLEIK
S2-4	P4	D7	QLQLVESGGGVVQPGRSLRVSCAASGFSLSTYAMHWVRQAPGK GLEWLADLSYEGSITHYAESVKGRFTISKDNSKNTLYLQMNSLRTD DTARYYCSRGGIAGREAFDLWGQGTMVTVSS	DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLIWFH QRPGQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLNINRV EAEDVGFYYCMQGTHWPLTFGGGTKVEIK
S2-5	P5	D7	EVHLVESGGDLVEPGGSLRLSCAASGFNFGNAWMSWVRQAPGK GLEWVARIKRETDGGATDYAAPVKGRFTISRDDSKSTLYLHMNSLK TEDAAVYYCTTDRRQDYDPQFDCWGQGTLVTVSS	DIVMTQSPDSLTVSLGERATINCKSSQSLSYSFNNKDYLGW YQKKPGQPPKMLIYWASARASGVPDRFSGSASGTDFTLTIS SLQAEDVAVYYCLQYYTYPRTFGQGTKVEIK
S2-6	P9	D28	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWVHWVRQAPGK GLVWVSRIREDGIFTTYADSVKGRFTISRDNARNTVSLQMNSLRAE DSAVYYCVRVKVDTDLVTADYWGQGTRVTVSS	QTVVTQEPSLTVSPGGTVTLTCASTTGAVTSDYYPNWFQQK PGQAPRALIYSTSNKHSWTPARFSGSLLGGKAALTLSGAQP EDEAEYYCLLYYGGTYVFGGTYVFGTGTKVTVL
S2-7	P4	D7	QVQLQESGPGLVKPSETLSLTCTVSGGSINSYYWSWVRQTPGKGL EWIGYIYYRGSTNYNPSLKSRVTISVDTSRNQFSLKLNSVTAADTAV YYCARESRDNWFDPWGQGTLVTVSS	DIVMTQSPDSLAVSLGERATIRCKSSQSVMYISNNKNYLAWY QQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSL QAEDVAIYYCQQYFNTPWTFGQGTKVEIK
S2-8	P4	D7	QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWSWVRQTPGKGL EWIGYVYYRGSTNYNPSLKSRVTMSVDTSRNQFSLRLNSVTAADT AVYYCARETRDNWFDSWGQGTLVTVSS	DILMTQSPDSLTASLGERATIKCKSSQSVMYNTNNKRYLAW YQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTIS SLQAEDVAIYYCQQYFDTPWTFGQGTKVEIK_
S2-9	P9	D28	EVNLVESGGGSVKPGGSLRLSCEVSGFTFSNGWMSWVRQVPGK GLEWVGRIKSKADGETTDYAAPVKGRFTIFRDDSKNTLFLQMNSLL MEDTAVYYCASEPPYTAYGRFDYWGQGTLVTVSS	DIQMTQSPSSLSASVGDRLTITCRASQNIGYSLNWYQLKPGK APKLLIYAASTLQSGVPSRFGGSGSGSGTDFTLTISSLQPEDFAT YYCQQSYSGLTWTFGQGTKVDIK

442 Materials and methods

443 Study design, sample collection, and storage

444 All studies were approved by the Institutional Review Board of Stanford University (IRB-3780),

- and the studies complied with the relevant ethical regulations. All participants provided written
- 446 informed consent before participating in the study. Nine healthy individuals were enrolled in the
- 447 study (Extended Data Table 1). All individuals had undergone routine RT-PCR testing prior to
- study. None of the participants had been previously diagnosed with SARS-CoV-2 infection.
- Blood samples were collected in heparin tubes (BD) at four different timepoints including pre-
- 450 vaccination (D0), 7- to 9 days post initial vaccination (D7), on the day of and prior to the second
- dose (21- to 23 days post initial vaccination, D21), and 28 to 30 days after initial and 7-9 days
- 452 after second vaccination (D28). Plasma samples were obtained after centrifugation, and stored at
- 453 -80°C. Peripheral Blood Mononuclear Cells (PBMCs) were obtained by density gradient
- 454 centrifugation over Ficoll PLUS media (Cytiva) and stored in cell freezing media (Thermo
- 455 Fisher Scientific). Plasma samples were aliquoted and stored until use at -80°C.
- 456 Generation of barcoded fluorescent antigen tetramers
- 457 Recombinant Avi-tag biotinylated SARS-CoV-2 S2 protein (Acro Biosystems, S2N-C52E8-
- 458 25ug), SARS-CoV-2 RBD (Acro, SPD-C82E9-25ug), and SARS-CoV-2 S1 (Acro, S1N-C82E8-
- 459 25ug) were mixed with barcoded, fluorescently labeled streptavidin (Biolegend) at a 4 to 1 molar
- ratios for 45 minutes while rotating. Excess biotin was added to saturate all streptavidin bindingsites.
- 462 Flow cytometry, cell sorting, and 10X sample preparation

463 PBMCs were thawed at 37C°, treated for 15min with DNAse and washed in complete RPMI.

464 PBMCs were enriched for B cells using the EasySep Human Pan-B Cell Enrichment Kit (Stem

- 465 Cell Technologies) according to the manufacturer instructions. B cell samples without antigen
- 466 enrichment were stained with CD19, IgD, CD27, CD38 TotalSeq-C antibodies (all Biolegend).
- 467 For antigen-sorted B cell samples, cells were stained with the following fluorescently labeled
- 468 antibodies according to standard protocols: CD19, CD20, CD38 (all BD Biosciences), CD3,
- 469 CD27, IgM, IgD, (all BioLegend), IgA (Miltenyi Biotec), Sytox blue (Thermo Fisher Scientific),
- 470 and S-antigen tetramers (Extended Data Fig. 3a,b,d). Additionally, samples were labeled with

- 471 TotalSeq-C hashtag 1-9 antibodies (Biolegend) for demultiplexing individual samples in
- 472 downstream analysis. Single cells were sorted with a FACSAria II cell sorter (BD Biosciences)
- 473 into cooled 1.5 ml tubes (BioRad). FlowJo Version 10.7.1 (BD Biosciences) and R version 3.6.1
- 474 was used for flow cytometry data analysis.

475 Droplet-based single-cell sequencing

476 Using a Single Cell 5' Library and Gel Bead Kit v1.1(10X Genomics, 1000165) and Next GEM

477 Chip G Single Cell Kit (10X Genomics, 1000120), the cell suspension was loaded onto a

478 Chromium single cell controller (10X Genomics) to generate single-cell gel beads in the

479 emulsion (GEMs) according to the manufacturer's protocol. Briefly, approximately 8,000 cells

- 480 were added to each channel and approximately 4,000 target cells were recovered. Captured cells
- 481 were lysed and the released RNA was barcoded through reverse transcription in individual
- 482 GEMs. 5' Gene expression (GEX) libraries, Single Cell V(D)J libraries (1000016), and Cell
- 483 surface protein libraries were constructed according to manufacturer protocols. Library quality
- 484 was assessed using a 2200 TapeStation (Agilent). The libraries were sequenced using an Illumina
- 485 Novaseq6000 sequencer with a paired-end 150-bp (PE150) reading strategy (Novogene).

486 Single cell RNA-seq data processing

487 Raw gene expression and cell surface matrices were generated for each sample by the Cell 488 Ranger Pipeline (v.6.0.1) coupled with human reference version GRCh38. Briefly, gene 489 expression analyses of single cells were conducted using the R package Seurat (v4.0.2) to 490 perform data scaling, transformation, clustering, dimensionality reduction, differential expression 491 analyses and most visualization³⁶. The count matrix was filtered to remove cells with >10% of 492 mitochondrial genes or low gene counts (<600 for enriched B cells, <200 for sorted B cells). The 493 normalized data were integrated into one Seurat data file using the IntegrateData function. 494 Principal component analysis was performed using variable genes. We compared the ranking of 495 principle components (PCs) with the percentage of variance and determined the number of first ranked PCs used to perform Uniform Manifold Approximation And Projection (UMAP)¹⁰ to 496 497 reduce the integrated dataset into two dimensions. Afterwards, the same number of first ranked 498 PCs were used to construct a shared nearest-neighbor graph (SNN), and this SNN used to cluster 499 the cells. For sorted cells, all sorted cells were used in the UMAP projection. For enriched B 500 cells, immune cell clusters were identified using canonical markers. Contaminant cells (non-B

501 cells) were removed and the data was normalized, integrated, and clustered with only the B cells.

502 Specific B cell clusters were identified using canonical B cell markers¹¹(Extended Data Fig. 1).

503 Identification of differentially expressed genes (DEG) and functional enrichment

504 We performed differential gene expression testing using the FindMarkers function in Seurat with

505 Wilcoxon rank sum test and the Benjamini–Hochberg method was used to adjust the p-values for

506 multiple hypothesis testing. DEGs were filtered using a minimum log₂(fold change) of 0.25 and a

507 maximum FDR value of 0.05. Pathway analysis for the DEGs was conducted using the

508 Metascape³⁵.

509 VDJ Sequence analysis

510 BCR VDJ regions were generated for each sample using the Cell Ranger Pipeline (v.6.0.1). BCR

511 sequences were then filtered to include cells that have one light and one heavy chain per cell.

512 Consensus sequences were aligned to germline variable-chain immunoglobulin sequences with

513 IMGT HighV-QUEST v1.8.3³⁷. Clonal expansions were defined based on sharing the same

heavy and light chain V and J genes with >70% amino acid identity in heavy and light chain

515 CDR3s.

516 Recombinant monoclonal antibody (rmAb) production

517 Heavy chain and light chain variable sequences were codon optimized and cloned into in-house

518 vectors, containing human IgG1 constant region or kappa or lambda constant regions,

respectively. Expi293F cells were transfected with heavy chain and light chain plasmids using

520 FectoPro (Polyplus transfection). Media was harvested after seven days, and rmAbs were

521 purified with AmMag Protein A magnetic beads (Genscript,). Antibody concentrations were

522 measured with a nanodrop spectrophotometer (Thermo Fisher Scientific) and human IgG

523 quantitation ELISAs (Bethyl Laboratories).

524 ELISA

525 For protein ELISAs, MaxiSorp 384-well plates (Thermo Fisher Scientific) were coated with 1

526 μg/ml recombinant SARS-CoV-2 S2 protein (Acro, S2N-C52H5), SARS-CoV-2 RBD (Acro,

527 SPD-C52H3), or SARS-CoV-2 S1 (Acro, S1N-C52H3), HCoV-OC43 Spike protein (Sino

528 Biological, 40607-V08B), HCoV-HKU1 Spike protein (Sino Biological, 40606-V08B), HCoV-

529 229E Spike protein (Sino Biological, 40605-V08B), HCoV-NL63 Spike protein (Sino

530 Biological, 40604-V08B) in carbonate-bicarbonate buffer at 4°C overnight. Plates were washed 6 531 times with PBST (PBS + 0.1% Tween20) after each step. The plates were blocked with blocking 532 buffer (PBS + 1% BSA) for 1 hour at room temperature. Human plasma was serially diluted, and 533 added for 1 hour at room temperature. Human rmAbs were added at concentrations of 10µg/ml 534 and three 10-fold serial dilutions, and incubated overnight at 4°C. Secondary HRP-conjugated 535 antibodies goat anti-human IgG (Bethyl Laboratories) or HRP-conjugated goat anti-human IgA 536 (Bethyl Laboratories) were applied for 1h at RT, and plates were developed with TMB substrate 537 (Thermo Fisher Scientific), and stopped with 2N sulfuric acid. Plates were read on a GloMax 538 Explorer Microplate Reader (Promega).

539 **Bio-Layer Interferometry**

540 rmAb interactions with S2, RBD, and S1 protein were measured on an Octet Red96e (Fortebio /

541 Sartorius). Association and dissociation curves were measured with rmAbs bound to anti-human

542 IgG Fc Capture (AHC) sensors at 20 nM and antigens in solution at 0, 16.7, 50, 150, and 450 nM

543 in 1x kinetic buffer (Fortebio / Sartorius). BLI analysis software (Fortebio / Sartorius) was used

544 for data processing and analysis. Buffer controls were subtracted from antigen values and curves

545 were fitted globally for each group, consisting of all concentrations of the same ligand.

546 Association and dissociation curves and constants as well as KD values for each antibody were

547 reported and graphed with GraphPad Prism.

548 Cell culture

- 549 Expi293F cells were cultured in 33% Expi293 Expression Medium (Gibco) and 67%
- 550 Freestyle293 Expression Medium (Gibco). HeLa-ACE2 were kindly provided by of Dennis
- 551 Burton³⁸ and were cultured in Eagle's Minimum Essential Medium (ATCC, 30-2003) with 10%
- heat-inactivated FBS (Corning) and 100 U/ml of penicillin-streptomycin (Gibco). Lenti X 293T
- cells (Takara Bio) were cultured in DMEM (ATCC, 30-2002) with 10% heat-inactivated FBS
- 554 (Corning) and 100 U/ml of penicillin–streptomycin (Gibco).

555 Generation SARS-CoV-2 spike pseudotyped lentiviral particles

- 556 Pseudotyped lentiviral particles were generated as previously described³⁹. Briefly, LentiX 293T
- cells were seeded in 10cm plates. After 24 hours, cells were transfected using Fugene
- transfection reagent (Promega) with pHAGE-CMV-Luc2-IRES-ZsGreen-W, lentiviral helper

plasmids (HDM-Hgpm2, HDM-tat1b, pRC-CMV-Rev1b), and wildtype or variant SARS-CoV-2

- 560 spike plasmids (parent plasmids publicly available from Jesse Bloom lab). After 48 to 60 hours,
- viral supernatants were collected and spun at 1000xg for 10m to remove cell debris. The
- 562 lentiviral supernatants were concentrated using LentiX concentrator (Takara) according to the
- 563 manufacturer's instructions. The lentiviral pellets were resuspended at 20-fold viral increase in
- 564 EMEM media and stored at -80°C. Virus was titrated on HeLa-ACE2 cells.

565 Viral inhibition assays

- 566 Neutralization assays were performed as previously described³⁹. Briefly, eight-fold serially
- 567 diluted plasma starting at 1:80 from vaccinated individuals or five-fold serially diluted
- 568 monoclonal antibodies starting at a concentration of 10µg/ml were incubated with SARS-CoV-2
- 569 pseudotyped virus for 1 hour at 37°C. The mixture was added to HeLa-ACE2 cells plated the
- 570 prior day. After ~50 hours post-infection, luciferase activity was measured on a GloMax
- 571 Explorer Microplate Reader (Promega).

572 Statistics and software

573 GraphPad Prism version 8.4.1 and R version 3.6.1 were used for statistical analyses. Statistical

- tests used and significance levels are indicated in the respective methods section or in the figure
- 575 legends. Graphical illustrations were created with BioRender.

576 Acknowledgements:

- 577 We thank all study participants who devoted time to our research. We thank Dennis Burton for
- 578 providing the ACE2-HeLa cells. We thank Matthew Baker for key discussions. We thank
- 579 Shaghayegh Jahanbani for antibody production. This work was supported by T32 AI007290-35
- to R.C.B.; National Science Foundation Graduate Research Fellowship to R.C.B; the German
- 581 Research Foundation (DFG, LA3657/1) to T.V.L.; NIH R01 AR063676 and U19 AI110491 to
- 582 W.H.R.
- 583

584 **Competing interests**

585 W.H.R. is a Founder, member of the Board of Directors, and consultant to

- 586 Atreca, Inc.
- 587
- 588

589 Author contributions	589	Author	contributions
--------------------------	-----	--------	---------------

- 590 Author contributions: Conceptualization, R.C.B., T.V.L., W.H.R.; Methodology, R.C.B., T.V.L.,
- 591 N.S.R., L.J.L.; Software, R.C.B., T.V.L.; Validation, R.C.B., T.V.L.; Formal Analysis, R.C.B.,
- 592 T.V.L.; Investigation, R.C.B., T.V.L.; Resources, R.C.B., T.V.L., W.H.R.; Data Curation,
- 593 R.C.B., T.V.L.; Writing Original Draft, R.C.B., T.V.L.; Writing Review & Editing, R.C.B.,
- 594 T.V.L., N.S.R., L.J.L., W.H.R.; Visualization, R.C.B., T.V.L.; Supervision, T.V.L., W.H.R.;
- 595 Project Administration, R.C.B., T.V.L., W.H.R.; Funding Acquisition, R.C.B., T.V.L., W.H.R.
- 596

597 Materials Availability

- 598 Materials generated in this study will be made available on request and may require a material
- 599 transfer agreement.
- 600

601 Data Availability Statements

602 The raw sequencing data will be uploaded in the GEO database before final publication.

603 References

- Amanat, F. *et al.* SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies
 to NTD, RBD, and S2. *Cell* (2021) doi:10.1016/j.cell.2021.06.005.
- Röltgen, K. *et al.* mRNA vaccination compared to infection elicits an IgG-predominant
 response with greater SARS-CoV-2 specificity and similar decrease in variant spike
 recognition. *medRxiv* (2021) doi:10.1101/2021.04.05.21254952.
- 609 3. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*.
- 610 *Engl. J. Med.* **383**, 2603–2615 (2020).
- 4. Vogel, A. B. *et al.* BNT162b vaccines protect rhesus macaques from SARS-CoV-2. *Nature*592, 283–289 (2021).
- 613 5. Wrapp, D. *et al.* Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion
- 614 Conformation. *bioRxiv* (2020) doi:10.1101/2020.02.11.944462.
- 615 6. Huang, Y., Yang, C., Xu, X.-F., Xu, W. & Liu, S.-W. Structural and functional properties of
- 616 SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta

- 617 *Pharmacol. Sin.* **41**, 1141–1149 (2020).
- 618 7. Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2
- 619 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* 183,
 620 1024–1042.e21 (2020).
- 8. Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody

622 neutralization. *Nature* (2021) doi:10.1038/s41586-021-03777-9.

- 623 9. Ehling, R. A. et al. Single-Cell Sequencing of Plasma Cells from COVID-19 Patients
- Reveals Highly Expanded Clonal Lineages Produce Specific and Neutralizing Antibodies to
 SARS-CoV-2. (2021) doi:10.2139/ssrn.3817802.
- Becht, E. *et al.* Dimensionality reduction for visualizing single-cell data using UMAP. *Nat. Biotechnol.* (2018) doi:10.1038/nbt.4314.
- 628 11. Sanz, I. *et al.* Challenges and Opportunities for Consistent Classification of Human B Cell
 629 and Plasma Cell Populations. *Front. Immunol.* 10, 2458 (2019).
- Krzyzak, L. *et al.* CD83 Modulates B Cell Activation and Germinal Center Responses. *J. Immunol.* 196, 3581–3594 (2016).
- Maddur, M. S. *et al.* Human B cells induce dendritic cell maturation and favour Th2
 polarization by inducing OX-40 ligand. *Nat. Commun.* 5, 4092 (2014).
- Bortnick, A. & Allman, D. What is and what should always have been: long-lived plasma
 cells induced by T cell-independent antigens. *J. Immunol.* 190, 5913–5918 (2013).
- 636 15. Cho, A. *et al.* Robust memory responses against influenza vaccination in pemphigus
 637 patients previously treated with rituximab. *JCI Insight* 2, (2017).
- 638 16. Fink, K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections.
 639 *Front. Immunol.* 3, 78 (2012).
- 640 17. Mei, H. E. *et al.* Blood-borne human plasma cells in steady state are derived from mucosal
 641 immune responses. *Blood* 113, 2461–2469 (2009).
- Krammer, F. The human antibody response to influenza A virus infection and vaccination. *Nat. Rev. Immunol.* 19, 383–397 (2019).
- McKean, D. *et al.* Generation of antibody diversity in the immune response of BALB/c
 mice to influenza virus hemagglutinin. *Proc. Natl. Acad. Sci. U. S. A.* 81, 3180–3184
 (1984).
- 647 20. Dugan, H. L. et al. Preexisting immunity shapes distinct antibody landscapes after influenza

- 648 virus infection and vaccination in humans. *Sci. Transl. Med.* **12**, (2020).
- Ladner, J. T. *et al.* Epitope-resolved profiling of the SARS-CoV-2 antibody response
 identifies cross-reactivity with endemic human coronaviruses. *Cell Rep Med* 2, 100189
 (2021).
- 652 22. Premkumar, L. *et al.* The receptor binding domain of the viral spike protein is an
- 653 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci*654 *Immunol* 5, (2020).
- 23. Ladner, J. T. *et al.* Epitope-resolved profiling of the SARS-CoV-2 antibody response
 identifies cross-reactivity with an endemic human CoV. *bioRxiv* (2020)
- 657 doi:10.1101/2020.07.27.222943.
- Kreer, C. *et al.* Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing
 Antibodies from COVID-19 Patients. *Cell* 182, 843–854.e12 (2020).
- 660 25. Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* 591, 639–644
 661 (2021).
- 662 26. Li, Q. *et al.* SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune
 663 escape. *Cell* 184, 2362–2371.e9 (2021).
- 27. Li, Q. *et al.* The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
 Antigenicity. *Cell* 182, 1284–1294.e9 (2020).
- Palm, A.-K. E. & Henry, C. Remembrance of Things Past: Long-Term B Cell Memory
 After Infection and Vaccination. *Front. Immunol.* 10, 1787 (2019).
- Lederer, K. *et al.* SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal
 Center Responses Associated with Neutralizing Antibody Generation. *Immunity* 53, 1281–
 1295.e5 (2020).
- 30. Turner, J. S. *et al.* SARS-CoV-2 mRNA vaccines induce persistent human germinal centre
 responses. *Nature* (2021) doi:10.1038/s41586-021-03738-2.
- 31. Zuccarino-Catania, G. V. *et al.* CD80 and PD-L2 define functionally distinct memory B cell
 subsets that are independent of antibody isotype. *Nat. Immunol.* 15, 631–637 (2014).
- 32. Abbott, R. K. *et al.* Precursor Frequency and Affinity Determine B Cell Competitive Fitness
 in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. *Immunity*48, 133–146.e6 (2018).
- 678 33. Turner, J. S. et al. Human germinal centres engage memory and naive B cells after

- 679 influenza vaccination. *Nature* **586**, 127–132 (2020).
- 680 34. Li, X. *et al.* Cbl Ubiquitin Ligases Control B Cell Exit from the Germinal-Center Reaction.
 681 *Immunity* 48, 530–541.e6 (2018).
- 35. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systemslevel datasets. *Nat. Commun.* 10, 1523 (2019).
- 684 36. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* 184, 3573–3587.e29
 685 (2021).
- Alamyar, E., Duroux, P., Lefranc, M.-P. & Giudicelli, V. IMGT(®) tools for the nucleotide
 analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires,
- 688 polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS.
- 689 *Methods Mol. Biol.* 882, 569–604 (2012).
- 690 38. Rogers, T. F. *et al.* Isolation of potent SARS-CoV-2 neutralizing antibodies and protection
- from disease in a small animal model. *Science* **369**, 956–963 (2020).
- 692 39. Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral Particles with
 693 SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* 12, (2020).